On the stock market since 2020, it operates in the world of health and science. It has 30 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 36% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $61.4M against $0 in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, CMPI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CMPI is a high-risk stock — not yet profitable, and its future rides on its product catching on.